Chesser et al.51 in this pilot, single-arm, interventional study assessed the usability and feasibility of 12 weeks' use of CGM in nine adolescents and young adults (13–21 years old) with T2D for ≥6 months, HbA1c >7.0%, and treated with basal insulin and/or noninsulin therapy (NIT); seven participants completed.51 At 12 weeks, participants reported statistically significant improvement in diabetes-related quality of life (QoL), with the mean Pediatric Quality of Life inventory (PedsQL)52 diabetes score increasing from 70 to 75 after using CGM (P = 0.026). Here, INS is linked to type 2 diabetes mellitus.